Shots:

• The P-III PROVENT- pre-exposure prophylaxis trial evaluates safety & efficacy of AZD7442 (300mg- IM) vs PBO in 5197 patients in a ratio (2:1) with COVID-19 across 87 sites in the US- UK- Spain- France & Belgium
• Results: AZD7442 (1st LAAB combination) showed a 77% reduction in risk of developing symptomatic COVID-19- 75% of patients had co-morbidities. The therapy was well tolerated & preliminary analyses showed balanced AEs
• The preliminary in vitro results showed that AZD7442 neutralizes SARS-CoV-2 viral variants- including the Delta variant. The company plans for regulatory submission of PROVENT & STORM CHASER data to health authorities for EUA or conditional approval of AZD7442

  | Ref: AstraZeneca | Image: Business Standard